RCEL vs. FNA, EYE, AXGN, BVS, AVNS, CBLL, IRMD, BFLY, SIBN, and KIDS
Should you be buying AVITA Medical stock or one of its competitors? The main competitors of AVITA Medical include Paragon 28 (FNA), National Vision (EYE), AxoGen (AXGN), Bioventus (BVS), Avanos Medical (AVNS), CeriBell (CBLL), Iradimed (IRMD), Butterfly Network (BFLY), SI-BONE (SIBN), and OrthoPediatrics (KIDS). These companies are all part of the "medical equipment" industry.
AVITA Medical vs.
AVITA Medical (NASDAQ:RCEL) and Paragon 28 (NYSE:FNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
In the previous week, Paragon 28 had 10 more articles in the media than AVITA Medical. MarketBeat recorded 12 mentions for Paragon 28 and 2 mentions for AVITA Medical. Paragon 28's average media sentiment score of 0.65 beat AVITA Medical's score of 0.28 indicating that Paragon 28 is being referred to more favorably in the news media.
AVITA Medical has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Paragon 28 has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
27.7% of AVITA Medical shares are held by institutional investors. Comparatively, 63.6% of Paragon 28 shares are held by institutional investors. 1.8% of AVITA Medical shares are held by insiders. Comparatively, 15.3% of Paragon 28 shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
AVITA Medical presently has a consensus target price of $18.00, suggesting a potential upside of 108.09%. Paragon 28 has a consensus target price of $15.60, suggesting a potential upside of 43.74%. Given AVITA Medical's higher probable upside, equities analysts clearly believe AVITA Medical is more favorable than Paragon 28.
AVITA Medical received 43 more outperform votes than Paragon 28 when rated by MarketBeat users. However, 83.33% of users gave Paragon 28 an outperform vote while only 69.03% of users gave AVITA Medical an outperform vote.
AVITA Medical has higher earnings, but lower revenue than Paragon 28. Paragon 28 is trading at a lower price-to-earnings ratio than AVITA Medical, indicating that it is currently the more affordable of the two stocks.
Paragon 28 has a net margin of -25.31% compared to AVITA Medical's net margin of -95.47%. Paragon 28's return on equity of -37.90% beat AVITA Medical's return on equity.
Summary
Paragon 28 beats AVITA Medical on 13 of the 19 factors compared between the two stocks.
Get AVITA Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AVITA Medical Competitors List
Related Companies and Tools
This page (NASDAQ:RCEL) was last updated on 1/21/2025 by MarketBeat.com Staff
